There's no sugar-coating it: GlaxoSmithKline (NYSE:GSK) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.
David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What's the Deadline to File Taxes in 2018?
Here's when your 2017 return is due. Pay attention!
What Will Strong Nerf Sales on Amazon Mean for Hasbro?
Amazon said Hasbro's Nerf N-Strike Elite Strongarm Blaster was the best-selling toy on Amazon over the holidays. That won't necessarily translate to a blockbuster quarter for the toymaker.
Are Strong Sales of Robotic Vacuums on Amazon Good News for iRobot?
Robotic vacuums were among the best-selling home items on Amazon over the holidays. Will that translate into strong results for iRobot?